Skip to main content
. 2021 Sep 27;106(1):351–355. doi: 10.4269/ajtmh.21-0595

Table 1.

Malaria outcomes at 8 weeks by study arm (N = 284)

Azithromycin (N = 150) Amoxicillin (N = 133) Odds Ratio or Mean Difference (95% CI) P value
Positive RDT for malaria 13 (8.7%) 15 (11.2%) 0.75 (0.34 to 1.63) 0.46
Fever* 7 (4.7%) 5 (3.7%) 1.26 (0.39 to 4.36) 0.70
Positive RDT plus fever* 6 (4.0%) 4 (3.0%) 1.35 (0.38 to 5.40) 0.64
Hemoglobin, g/dL2 9.2 (1.2) 9.3 (1.5) −0.07 (−0.44 to 0.30) 0.70
Anemia (< 11.0 g/dL) 94 (92.2%) 81 (86.2%) 1.93 (0.77 to 5.09) 0.17
Received medical care since last study visit
 Week 1 5 (3.3%) 7 (5.2%) 0.62 (0.18 to 1.98) 0.42
 Week 2 6 (3.9%) 7 (5.1%) 0.75 (0.24 to 2.32) 0.62
 Week 3 8 (5.5%) 5 (3.7%) 1.50 (0.49 to 5.06) 0.49
 Week 4 6 (4.1%) 5 (3.8%) 1.08 (0.32 to 3.83) 0.90
 Week 8 9 (6.3%) 9 (7.5%) 0.83 (0.32 to 2.21) 0.71

CI = confidence interval; RDT = rapid diagnostic test.

*

Fever defined as tympanic temperature > 37.5°C.

In subset with hemoglobin measurements at 8 weeks (N = 196).

Received care at a primary healthcare facility per caregiver report.